Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trial.

Cathrine RambergKristian HindbergJoseph S BiedermannSuzanne C CannegieterFelix J van der MeerOmri SnirFrank W G LeebeekMarieke J H A KruipJohn-Bjarne HansenWillem M Lijfering

Published in: Journal of thrombosis and haemostasis : JTH (2022)

Rosuvastatin treatment caused a substantial decrease in plasma PPL activity, suggesting that a PPL-dependent attenuation of coagulation activation may contribute to a reduced VTE risk following statin treatment.

Keyphrases

venous thromboembolism
cardiovascular disease
combination therapy
fatty acid
replacement therapy